These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 37446055)

  • 1. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy.
    Wang Y; Wang L; Seo N; Okumura S; Hayashi T; Akahori Y; Fujiwara H; Amaishi Y; Okamoto S; Mineno J; Tanaka Y; Kato T; Shiku H
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug.
    Tanaka Y; Murata-Hirai K; Iwasaki M; Matsumoto K; Hayashi K; Kumagai A; Nada MH; Wang H; Kobayashi H; Kamitakahara H; Okamura H; Sugie T; Minato N; Toi M; Morita CT
    Cancer Sci; 2018 Mar; 109(3):587-599. PubMed ID: 29288540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.
    Tang C; Zhang Y
    Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells.
    Okuno D; Sugiura Y; Sakamoto N; Tagod MSO; Iwasaki M; Noda S; Tamura A; Senju H; Umeyama Y; Yamaguchi H; Suematsu M; Morita CT; Tanaka Y; Mukae H
    Front Immunol; 2020; 11():1405. PubMed ID: 32793196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.
    Zhai X; You F; Xiang S; Jiang L; Chen D; Li Y; Fan S; Han Z; Zhang T; An G; Zhang B; Chen Y; Meng H; Yang L
    Am J Cancer Res; 2021; 11(1):79-91. PubMed ID: 33520361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy harnessing γδ T cells and programmed death-1.
    Tanaka Y
    Immunol Rev; 2020 Nov; 298(1):237-253. PubMed ID: 32888218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.
    Tanaka Y; Iwasaki M; Murata-Hirai K; Matsumoto K; Hayashi K; Okamura H; Sugie T; Minato N; Morita CT; Toi M
    Sci Rep; 2017 Jul; 7(1):5987. PubMed ID: 28729550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.
    Du SH; Li Z; Chen C; Tan WK; Chi Z; Kwang TW; Xu XH; Wang S
    PLoS One; 2016; 11(9):e0161820. PubMed ID: 27598655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic β-Adrenergic Receptor Activation Augments the
    Baker FL; Bigley AB; Agha NH; Pedlar CR; O'Connor DP; Bond RA; Bollard CM; Katsanis E; Simpson RJ
    Front Immunol; 2019; 10():3082. PubMed ID: 32038628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies.
    Dhakal B; Chhabra S; Savani BN; Hamadani M
    Br J Haematol; 2022 Apr; 197(1):28-40. PubMed ID: 34671973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.
    Deniger DC; Switzer K; Mi T; Maiti S; Hurton L; Singh H; Huls H; Olivares S; Lee DA; Champlin RE; Cooper LJ
    Mol Ther; 2013 Mar; 21(3):638-47. PubMed ID: 23295945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
    Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
    Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials.
    Moradi V; Omidkhoda A; Ahmadbeigi N
    Biomed Pharmacother; 2023 Dec; 169():115888. PubMed ID: 37979380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
    Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
    Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
    Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
    Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of allogeneic CAR T-cells].
    Alcazer V; Depil S
    Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in Allogeneic Chimeric Antigen Receptor T Cells].
    Zhao Q; Li F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):967-972. PubMed ID: 38173109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.